Fortress Biotech Inc FBIO:NASDAQ

Last Price$0.86NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change+0.06(7.29%)
Bid (Size)$0.90 (11)
Ask (Size)$0.95 (1)
Day Low / High$0.83 - 0.97
Volume695.7 K
  • Latest Stories
  • Commentary and Analysis
-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q1 Revenue $23.9M, vs. Street Est of $20.7M
4:04PM ET 5/12/2022 MT Newswires

...

-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q1 Loss $-0.10, vs. Street Est of EPS $0.01
4:03PM ET 5/12/2022 MT Newswires

...

--Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating
11:34AM ET 3/29/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Fortress Biotech Starts Mid-Stage Triplex Vaccine Trial in Adults with HIV, Cytomegalovirus
10:56AM ET 12/16/2021 MT Newswires

Fortress Biotech (FBIO) on Thursday said that it has commenced a phase 2 trial to evaluate the safety, efficacy, and immunogenicity of Triplex in eliciting...

-- Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 EPS $0.54
4:03PM ET 11/15/2021 MT Newswires

...

-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q3 Revenue $21.1M
4:01PM ET 11/15/2021 MT Newswires

...

Journey Medical Corp. Prices IPO at $10 Per Share
7:52AM ET 11/12/2021 MT Newswires

Journey Medical Corp., a subsidiary of Fortress Biotech (FBIO), on Friday priced its initial public offering of about 3.52 million common shares at $10...

Fortress Biotech's Journey Medical Launches Initial Public Offering for Nasdaq Listing
12:42PM ET 11/08/2021 MT Newswires

Journey Medical Corporation, a unit of Fortress Biotech (FBIO), said Monday it has commenced an initial public offering of 3.2 million shares at $10 to $12...

Fortress Biotech Says Pivotal Studies of CUTX-101 in Patients With Menkes Disease Meet Endpoints
4:07AM ET 10/14/2021 MT Newswires

Fortress Biotech (FBIO) said Wednesday CUTX-101 met both primary and secondary efficacy endpoints in two pivotal studies in patients with Menkes disease, a...

Fortress Biotech, Cyprium Therapeutics Report Positive Clinical Data for Menkes Disease
9:04AM ET 10/08/2021 MT Newswires

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), said Friday that with support from licensing partner Sentynl Therapeutics it obtained...